Systematic review genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases by Sørensen, Signe Bek et al.
Syddansk Universitet
Systematic review genetic biomarkers associated with anti-TNF treatment response in
inflammatory bowel diseases
Sørensen, Signe Bek; Nielsen, Jakob V.; Bo Bojesen, Anders; Franke, A; Bank, Steffen;
Vogel, U; Andersen, Vibeke
Published in:
Alimentary Pharmacology and Therapeutics
DOI:
10.1111/apt.13736
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC
Citation for pulished version (APA):
Sørensen, S. B., Nielsen, J. V., Bo Bojesen, A., Franke, A., Bank, S., Vogel, U., & Andersen, V. (2016).
Systematic review genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel
diseases. Alimentary Pharmacology and Therapeutics, 44(6), 554-567. DOI: 10.1111/apt.13736
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Systematic review: genetic biomarkers associated with
anti-TNF treatment response in inﬂammatory bowel diseases
S. Bek*, J. V. Nielsen*, A. B. Bojesen†, A. Franke‡, S. Bank*, U. Vogel§ & V. Andersen*,¶,**,††
*Molecular and Diagnostic Research
Unit, Hospital of Southern Jutland,
Aabenraa, Denmark.
†Research Unit for E-mental Health,
Mental Health Services in the Region
of Southern Odense, Odense,
Denmark.
‡Institute of Clinical Molecular
Biology, Christian-Albrechts-University
of Kiel, Kiel, Germany.
§National Research Centre for the
Working Environment, Copenhagen,
Denmark.
¶Institute of Molecular Medicine,
University of Southern Denmark,
Odense, Denmark.
**Institute of Regional Health
Research, University of Southern
Denmark, Odense, Denmark.
††OPEN, University of Southern
Denmark, Odense, Denmark.
Correspondence to:
Dr V. Andersen, Molecular and
Diagnostic Research Unit, Kristen
Philipsens Vej 15, DK-6200 Abenra,
Denmark.
E-mail: vandersen@health.sdu.dk
Publication data
Submitted 23 February 2016
First decision 20 March 2016
Resubmitted 30 May 2016
Resubmitted 29 June 2016
Accepted 29 June 2016
EV Pub Online 15 July 2016
The Handling Editor for this article was
Professor Jonathan Rhodes, and it was
accepted for publication after full
peer-review.
SUMMARY
Background
Personalised medicine, including biomarkers for treatment selection, may provide
new algorithms for more effective treatment of patients. Genetic variation may
impact drug response and genetic markers could help selecting the best treatment
strategy for the individual patient.
Aim
To identify polymorphisms and candidate genes from the literature that are associ-
ated with anti-tumour necrosis factor (TNF) treatment response in patients with
inﬂammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis.
Methods
We performed a PubMed literature search and retrieved studies reporting original
data on association between polymorphisms and anti-TNF treatment response and
conducted a meta-analysis.
Results
A functional polymorphism in FCGR3A was signiﬁcantly associated with anti-TNF
treatment response among CD patients using biological response criterion (decrease in
C-reactive protein, levels). Meta-analyses showed that polymorphisms in TLR2
(rs3804099, OR (95% CI) = 2.17 (1.35–3.47)], rs11938228 [OR = 0.64 (0.43–0.96)],
TLR4 (rs5030728) [OR = 3.18 (1.63–6.21)], TLR9 (rs352139) [OR = 0.43 (0.21–0.88)],
TNFRSF1A (rs4149570) [OR = 2.06 (1.02–4.17)], IFNG (rs2430561) [OR = 1.66 (1.05–
2.63)], IL6 (rs10499563) [OR = 1.65 (1.04–2.63)] and IL1B (rs4848306) [OR = 1.88
(1.05–3.35)] were signiﬁcantly associated with response among IBD patients using clini-
cal response criteria. A positive predictive value of 0.96 was achieved by combining ﬁve
genetic markers in an explorative analysis.
Conclusions
There are no genetic markers currently available which are adequately predictive of
anti-TNF response for use in the clinic. Genetic markers bear the advantage that
they do not change over time. Therefore, hypothesis-free approaches, testing a
large number of polymorphisms in large, well-characterised cohorts, are required
in order to identify genetic proﬁles with larger effect sizes, which could be
employed as biomarkers for treatment selection in clinical settings.
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INTRODUCTION
The inﬂammatory bowel diseases (IBD) ulcerative colitis
(UC) and Crohn’s disease (CD) are inﬂammatory disor-
ders primarily affecting the gut.1 The incidence is increas-
ing worldwide and IBD may affect up to 1% of the
population.2 Both CD and UC have a major impact on
the quality of life of the patients and their families due to
debilitating symptoms and also for the society due to
absence from work and health care expenses. IBD is con-
sidered to develop as a result of a persistent perturbation
of the interaction between the gut microbiota and the
host immune system resulting in changes in the micro-
biome (dysbiosis) and in mucosal inﬂammation.3 Stimu-
lation of toll-like receptors and nod-like receptors on
epithelial cells and local immune cells by microbes induce
various pathways that mediate the secretion of the pro-
inﬂammatory cytokines interleukine (IL)-17, IL-6, inter-
feron-c, and tumour necrosis factor-a (TNF)4–8 resulting
in disruption of the barrier function (mainly in UC), dys-
function of microbe sensing (mainly in CD), and changes
in the regulation of adaptive immune responses (in both
disorders).8 The biological activity of TNF is mediated by
its binding to TNF receptor type 1 (TNFR1) and type 2
(TNFR2). After binding to the receptors, TNF initiates
cell proliferation, differentiation and pro-inﬂammatory
signalling [via activation of the nuclear factor-jB (NF-
jB) and mitogen-activated protein kinases (MAPK) path-
ways].9 Additionally, TNF signalling induces apoptosis of
intestinal epithelial cells as well as inducing changes in
the epithelial expression of tight junction proteins (via
caspase-8 activation).9 Hence, increased TNF-a expres-
sion might decrease the mucosal barrier function.9
Biologics are bioengineered therapeutic agents target-
ing a gene or a protein. The management of IBD has
changed signiﬁcantly during the last decade due to the
availability of anti-TNF.10, 11 They act through targeting
and neutralising the effect of TNF thereby diminishing
the downstream effects of TNF activation. However, the
pharmacodynamics of anti-TNF drugs seems to depend
on other factors than simply the TNF-binding capaci-
ties.9 Hence, their precise mechanism of action remains
unclear. Anti-TNF drugs have proven highly effective for
many patients, yet, a signiﬁcant proportion of the
patients do not respond to the treatment (i.e., ‘primary
failures’) due to e.g. genetics or loss of effect over time
to become intolerant due to the development of antibod-
ies to the treatment (i.e., ‘secondary failures’).9–11
Currently, much effort has been put into developing
biologics targeting various players in the immune
cascade which are involved in IBD,4 including cytokines,
cytokine receptors, B- and T-cell surface proteins, cell
adhesion molecules, and signal transduction pathways.12
Various immune players may be driving the disease in
various patients and the detection of which are the most
prominent in the individual patient will be necessary for
selecting the best treatment strategy. Until now, the
strategy for testing these new biologics in clinical settings
used to be ‘one drug suits all’, although they may be
beneﬁcial in only a subset of patients characterised by a
speciﬁc target. Thereby, theoretically, the effect of biolog-
ics on a speciﬁc subset of the patients may not be
detected.
‘Personalised Medicine refers to a medical model
using characterisation of individual’s phenotypes and
genotypes (e.g. molecular proﬁling, medical imaging, life-
style data) for tailoring the right therapeutic strategy for
the right person at the right time, and/or to determine
the predisposition to disease and/or to deliver timely and
targeted prevention’.13 According to the Strategic
Research and Innovation Agenda (SRIA), European
Union, ‘Personalised Medicine represents one of the
most innovative new concepts in health care. It holds
real promise for more effective early diagnosis and more
effective and less toxic treatments for patients, for
improved medical service to citizens, and for improving
the overall health of the population’.13
Recently, interest in exploring the potentials of per-
sonalised medicine in IBD has raised.14–16 Accordingly,
clinical factors associated with anti-TNF response in CD
has been reviewed.15, 17 In CD, young age, short disease
duration, and luminal disease were associated with bene-
ﬁcial response and smoking was associated with nonre-
sponse.17 Pre-treatment C-reactive protein (CRP) levels
and serological markers may also have predictive value.17
The knowledge on factors associated with TNF response
in UC are even more scarce.18
Pharmacogenetic studies may help identifying patients
likely to beneﬁt from a given treatment and the actual
pathways by which a drug works.19, 20 Furthermore, the
identiﬁcation of genetic proﬁles characterising the nonre-
sponders may lead to understanding of the mechanisms
that are active in the nonresponders and may suggest
target(s) for treatment strategies in these patients. In
pharmacogenetic studies in general, polymorphisms in
both the pharmacodynamic (the ‘action’ of the drug) as
well as in the pharmacokinetic (the ‘fate’ of the drug)
pathways may be relevant in predicting the outcome of
the treatment. Genetic variants have already found their
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way into clinical practice for treatment selection of e.g.
hepatitis and colorectal cancer.21, 22 Thus, genetic vari-
ants enabling the prediction of anti-TNF treatment
response may help optimising treatment of the individual
patients, improve the use of the health care resources
and reduce adverse side-effects.
In order to drive the development of personalised medi-
cine in IBD, we conducted a systemic review of the current
knowledge on genetic variants associated with anti-TNF
treatment response in patients with IBD. Our aim was to
identify potential candidates for further evaluation and
putative predictive biomarkers should subsequently be eval-
uated, validated and eventually adopted for clinical use.
Thus, this review deals with primary response which should
be distinguish from secondary loss of response, i.e. the situ-
ation when a patient loses response after initial response.
MATERIALS AND METHODS
A systematic review and meta-analysis were carried out
according to the guidelines of ‘Preferred Reporting Items
for Systematic Reviews and Meta-Analyses’ (PRISMA)
statement.23 To identify the relevant primary literature
three individual searches were performed in PubMed
using various alternative search terms for (i) “anti-TNF
treatment”, (ii) “genetic variation”, and (iii) “autoimmune
disease”, respectively. Subsequently, studies appearing in
all of the three searches were identiﬁed resulting in 572
abstracts (latest search date: 27 October 2015). Figure 1
shows the search strategy and a full list of search terms is
shown in Table S1. All studies suggesting that they pre-
sented original data on polymorphisms and anti-TNF
treatment response were retrieved (138 articles) and
reviewed by three independent authors (SB, JVN, VA).
Studies were excluded due to small numbers of study par-
ticipants for treatment evaluation (less than 100 cases),
missing data, not reporting original data and not report-
ing data on anti-TNF response (78 studies). In total, 60
studies reported on genetic markers and anti-TNF
response in autoimmune diseases whereof 15 reported on
IBD (and the others on ankylosing arthritis, psoriasis and
rheumatoid arthritis). No further studies were identiﬁed
by searching the literature list of the retrieved articles.
Data from articles with available data on Odds ratios
(OR) and 95% conﬁdence intervals (CI) or numbers of
responders (complete or partial), nonresponders, and
genotypes were included.
Statistical methods
All polymorphisms studied in at least two studies and
where data on genotypes and treatment response could
be retrieved, were included in a meta-analysis. The meta-
analysis was based on total number of patients in the
included cohorts. Analyses were performed in STATA ver-
sion 14 (StataCorp, College Station, TX, USA) using the
meta-analysis plugin, metan. OR’s were pooled using the
Mantel–Haenszel approach for ﬁxed effects.24
To illustrate the potential predictive value of genetic
variants, we analysed original data from Bank et al.25
We made an initial screening of all individual polymor-
phisms in a series of logistic regressions predicting non-
response. The logistic outcome was code 0 for full or
partial response and 1 for nonresponse. On this basis we
identiﬁed ﬁve different genotypes signiﬁcantly associated
with nonresponse among UC patients (TLR2
rs4696480TT, TLR2 rs11938228AC, IL6 rs10499563TT,
IL12B rs3212227AC and IL12B rs3212217CG). Next, we
combined these ﬁve genotypes into a simple sum score
(0 if none were present, 1 if one were present, etc, and 5
if all ﬁve were present). These sum scores were used to
predict nonresponse (0 = full or partial response,
1 = nonresponse). Lastly, we calculated positive and neg-
ative predictive values for the sum scores. The negative
predictive value reﬂects the proportion of patients with a
particular genetic proﬁle that did not respond to anti
TNF treatment. Similarly, the positive predictive value
expresses the proportion of patients with a particular
genetic proﬁle that did respond to anti TNF treatment.
P-value <0.05 was considered statistically signiﬁcant.
RESULTS
Table 1 summarises the details of the retrieved studies.
No published genome-wide association study on anti-TNF
response in IBD including more than 100 treated cases
was identiﬁed. In total, 15 studies were included in the
analysis. All 15 studies were case–case studies employing a
candidate gene design.25–39 Fifteen studies reported associ-
ations between polymorphisms and treatment response in
CD26–39 and one article reported, in addition to the CD
study also a study on UC patients.25 The studies differed
according to the studied population, response criteria, and
elapsed time before evaluation of response (Table 1).
The polymorphisms investigated in relation to the
outcome from anti-TNF treatment of patients with CD
and UC are shown in Table 2. The OR and 95% CI for
the associations between the polymorphisms and the
treatment responses for the polymorphisms that were
assessed in more than one cohort were retrieved (Clinical
response criteria in Table 3 and biological response crite-
ria in Table 4). In total, 23 polymorphisms in 18 genes
were assessed in more than one cohort.
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The FCGR3A rs396991 polymorphism has been most
intensely investigated29, 34, 35, 37 (Tables 3 and 4). This
polymorphism has been evaluated both in relation to
clinical and biological response criteria.29, 34, 35, 37 First,
Louis et al. studied biological response rate from anti-
TNF treatment among 145 patients for whom the CRP
level prior to treatment were elevated compare to stan-
dard levels.29 Complete biological response was deﬁned
as a normalisation of CRP levels and partial response as
a decrease of at least 25% from the basal level. A com-
plete or partial biological response was observed in 100%
of 29 TT carriers compared to 70% of 71 GG or TG car-
riers (P = 0.0002). In contrast, no signiﬁcantly different
response rates between the genotypes were found when
using clinical response criteria.29 Similarly, results were
reported from the ACCENT study.34 Again, no differ-
ences were found in relation to clinical criteria. However,
analyses of the subgroup with baseline CRP values
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Figure 1 | Flow chart for studies included in this review.
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Table 1 | Description of the 15 studies of association between polymorphisms and response to anti-TNF treatment
Disease Ethnicity/Country
Treatment
Drug(s)
Response
criteria based on Response time N cases References
CD Multicenter* Inﬂiximab CDAI† 2 weeks 90 + 444 Mascheretti et al.27
CD Belgium Inﬂiximab CDAI† or ﬁstula‡ 4 and 10 weeks 245 Vermeire et al.38
CD Belgium Inﬂiximab CDAI† or ﬁstula
number‡
4 weeks 226 Louis et al.28
CD Multicenter* Inﬂiximab CDAI† 4 weeks 90 + 444 Mascheretti et al.26
CD Belgium Inﬂiximab CDAI†, ﬁstula§,
or CRP¶, CRP**
4 weeks 145 Louis et al.29
CD Belgium Inﬂiximab CDAI† or CRP†† 4 and 8 weeks 166 Pierik et al.30
CD Belgium Inﬂiximab CDAI† or ﬁstula§
or CRP‡‡
4 and 10 weeks 204 Hlavaty et al.39
CD Belgium Inﬂiximab CDAI†,§§, ﬁstula§,
or CRP¶,**
10 weeks 189 Willot et al.31
CD Caucasian Inﬂiximab CDAI† or ﬁstula‡
or CRP***
12 weeks 150 Dideberg et al.32
CD Caucasian Inﬂiximab CDAI†, ﬁstula§,
CRP**,¶¶
4 and 10 weeks 222 Dideberg et al.33
CD 95.3%
Caucasian
Inﬂiximab CDAI†,§§ or
ﬁstula‡ or CRP¶,**
2 and 6 weeks 344/156 Louis et al.34
CD Japan Inﬂiximab CDAI§§, CRP** 4, 8 and 30 weeks 102 Moroi et al.35
CD Caucasian
(Spanish)
Inﬂiximab HBI***, ﬁstula§ 10 weeks 297 Medrano et al.36
CD Denmark Inﬂiximab/
Adalimumab
SCTSS††† Within 22 weeks 482 Bank et al.25
CD Slovenian Adalimumab IBDQ‡‡‡, CRP‡‡ 4, 12, 20 and 30 weeks 102 Koder et al.37
UC Denmark Inﬂiximab/
Adalimumab
SCTSS††† Within 22 weeks 256 Bank et al.25
* German (cohort I), North America, Europe, Canada, Israel (cohort II).
† Crohn’s disease activity index (CDAI); Clinical response (remission): CDAI below 150, partial response (response): drop of at
least 70 CDAI points.
‡ Fistula number: Complete response (remission): at least 50% reduction in number of ﬁstulae from baseline at two consecutive
visits.
§ Fistula number: Complete response (remission): complete ﬁstula closure, partial response: at least 50% reduction in number of
ﬁstulae from baseline at two consecutive visits.
¶ C-reactive Protein (CRP); Biological response: drop in CRP to normal values (<3 mg/L), partial response: drop in CRP level of
more than 25%.
** CRP, decrease in CRP, absolute and/or relative values, among entire cohort or subgroup having elevated CRP concentrations.
†† CRP; Biological remission were deﬁned as a normalisation (<3 mg/L) and biological response was deﬁned as a >12 mg/L
decrease (the mean decrease in CRP) of CRP.
‡‡ C-reactive protein (CRP); Biological response: drop in CRP to normal values (<3 mg/L) or drop in CRP level of more than
25%.
§§ CDAI, decrease in CDAI, absolute and/or relative.
¶¶ CRP; Response was deﬁned as a drop in CRP level of more than 25% among patients with an elevated CRP before treatment
(more than twice the upper limit of the normal range).
*** Harvey–Bradshaw index (HBI); Clinical response (remission): a ﬁnal HBI lower than 4 and absence of concomitant corticos-
teroids, partial response (response): a decreased in HBI by more than 3 points and absence of concomitant corticosteroids.
††† Simple Clinical Three Step Scale (SCTSS); Response: absence or near absence of all clinical symptoms without increase in
corticosteroids, Partial response: improvement or tapering of corticosteroids without worsening, nonresponse: No change or
worsening of symptoms.
‡‡‡ IBD questionnaire (IBDQ); Clinical response was deﬁned as an increase in IBDQ of at least 22 or an IBDQ of at least 170.
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Table 2 | Investigated polymorphisms in relation to anti-TNF treatment response in Crohns Disease (CD) and
ulcerative colitis (UC)
Disease References
# SNPs
assigned
# sign
SNPs
Gene (rs-number)
Signiﬁcant SNPs Nonsigniﬁcant SNPs
CD Mascheretti et al.27 11 2 TNFRSF1B (rs1061622)
TNFRSF1B (exon 2)
TNF (rs361525, rs1800629,
rs1800750, rs1799724, rs1799964),
TNFRSF1A (rs4149570, rs767455),
TNFRSF1B (rs1061624, rs3397)
CD Vermeire et al.38 3 0 NOD2 (rs2066845, rs2066844,
rs41450053)
CD Louis et al.28 1 0 TNF (rs1800629)
CD Mascheretti et al.26 3 0 NOD2 (rs2066845, rs2066844, rs41450053)
CD Louis et al.29 1 0 FCGR3A (rs396991)
CD Pierik et al.30 2 0 TNFRSF1A (rs767455) TNFRSF1B (rs1061622)
CD Hlavaty et al.39 17 2 FAS (rs763110)
CASP9 (rs4645983)
FAS (rs1800682, rs3218621,
rs2234978, rs3218611),
TRAIL DR4 (rs6557634, rs4871857),
CASP3 (rs1049210), CASP9 (rs1052571,
rs1132310, rs4646008, rs2308938, rs2020897),
BAD (rs3729933), BCL2L1 (rs7362890),
API4 (rs2071214)
CD Willot et al.31 4 0 CRP (rs2794521, rs1130864, rs1205)
CD Dideberg et al.32 6 0 LTA (rs909253, rs2857713, rs5875327, rs1041981,
rs746868, rs3093543)
CD Dideberg et al.33 12 0 ADAM17 (rs2001658, rs12469362, rs883399,
rs1048610, rs2276338, rs1056204, rs10929587,
rs1880439, rs10495565, rs4464248, rs11684747,
rs10929590)
CD Louis et al.34 1 0 FCGR3A (rs396991)
CD Moroi et al.35 1 0 FCGR3A (rs396991)
CD Medrano et al.36 4 2 TNFRSF1B (rs1061624) TNFRSF1A (rs767455),
TNFRSF1B (rs1061622, rs3397)
CD Koder et al.37 33 10 CASP9 (rs4645983)
PTGER4 (rs10512734)
IL27 (rs8049439)
C11orf30 (rs7927894)
CCNY (rs12777960)
NR12 (rs3814057)
IL13 (rs1295686)
ATG16L1 (rs10210302)
FCGR3A (rs3969919)
FAS (rs1800682)
IL10 (rs3024505)
TNFRSF14 (rs3748816)
10p11.2 (rs4934697),
10q21 (rs10509115), c110rf30 (rs7927894)
CTLA4 (rs3087243), DLG5 (rs1248696),
ECM1 (rs13294), IL12A (rs17810546), IL12B
(rs6887695), IL12RB1 (rs11575934), IL23R
(rs7517847), IL4 (rs2070874), IL4R (rs1801275),
NKX2-3 (rs11190140), NOD2 (rs2066844,
rs2066845, rs41450053), NR1/2 (rs3814057),
ORMDL3 (rs2872507), PTPN22 (rs2476601),
SEPHS1 (rs2254252), SLC22A4 (rs1050152),
SLC22A5 (rs2631372), TNFSF15 (rs4263839)
CD Bank et al.25 36 7 TLR2 (rs1816702)
TLR2 (rs3804099)
TLR4 (rs5030728)
TLR9 (rs352139)
LY96 (rs11465996)
TNFRSF1A (rs4149570)
IFNG (rs2430561)
TLR2 (rs11938228, rs4696480),
TLR4(rs1554973, rs12377632),TLR5 (rs5744168),
TLR9 (rs187084), CD14 (rs2569190), MAP3K14
(rs7222094), SUMO4 (rs237025), NFKBIA
(rs696), NFKB1 (rs28362491), TNF (rs1800629,
rs361525), ;TNFAIP3 (rs6927172), IL1B
(rs4848306, rs1143623, rs1143627), IL1RN
(rs4251961), IL4R (rs1805010), IL6 (rs10499563),
IL6R (rs4537545), IL10 (rs1800872, rs3024505),
IL17A (rs2275913), IL23R (rs11209026), TGFB1
(rs1800469), PTPN22 (rs2476601), PPARG
(rs1801282), NLRP3 (rs4612666)
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within the two highest quartiles (N = 156) showed a
trend towards a greater relative change in CRP in the
TT carriers [the median decrease of CRP were 80, 77
and 64% among TT, TG and GG genotype carriers
(P = 0.085) after 6 weeks, respectively]. The authors also
observed the same trend at week 2.34 Similar results were
found in another study by Moroi et al., who found a sig-
niﬁcantly larger decrease of CRP (DCRP) and percentage
decrease (DCRP%) among 12 TT genotype carriers than
among 38 TG and 52 GG genotype carriers (P = 0.001
and P = 0.044, respectively) at week 8 whereas no differ-
ences were found at week 30 and no differences were
found in relation to the clinical response criteria.35
FCGR3A encodes a receptor for immunoglobulin G
(IgG), FccRIIIa. Moroi et al. moreover conducted an
in vitro experiment, assessing the binding afﬁnity of
inﬂiximab to natural killer (NK) cells and the inﬂiximab-
mediated antibody-dependent cell-mediated cytotoxicity
of peripheral blood mononuclear cells (PMBC) from six
healthy volunteers of each genotype.35 The authors
reported that NK cells from FCGR3A rs396991 TT
donors had signiﬁcantly higher binding afﬁnity to inﬂix-
imab compared to donors with the GG genotype
(P < 0.05). In addition PMBCs from FCGR3A rs396991
TT donors induced signiﬁcantly higher inﬂiximab-
mediated antibody-dependent cell-mediated cytotoxicity,
than cells from the GG donors (P < 0.05).35 Subse-
quently, Koder et al. reported no signiﬁcant association
between anti-TNF response and either clinical or biologi-
cal response.37 Clinical response was based on an IBDQ
and deﬁned as an IBDQ value higher than 170 points or
an increase in IBDQ of more than 22 points (DIBDQ
>22).40
Figures 2 and S1 show the results of the meta-analyses
including the retrievable data for all polymorphisms
studied in at least two studies. In total, eight polymor-
phisms in seven genes were found to be signiﬁcantly
associated with treatment response (Figure 2). All eight
polymorphisms were identiﬁed in one study including
both a CD and an UC cohort.25 The genes were TLR2,
TLR4, TLR9, TNFRSF1A, IFNG, IL6 and IL1B. Further-
more, nine polymorphisms in eight genes (TLR2, CD14,
LY96, TNF, TNFRSF1B, TNFAIP3, IL1RN and IL17A)
were not associated with treatment result (Figure S1). In
addition, three polymorphisms in NOD2 and a marker
polymorphism near IL10 were not associated with treat-
ment response in more than one individual study
(Table 3).
The predictive potential of ﬁve polymorphisms was
estimated based on original data supplied by Bank
et al.25 (Figure 3 and Table 5). We ﬁrst used logistic
regression to identify ﬁve genotypes (2 in TLR2, 2 in
IL12B, and 1 in IL6) that were signiﬁcantly associated
with an increased risk of anti-TNF nonresponse. As sim-
ple binary predictors they were only modestly associated
with nonresponse (OR < 2, results not shown). These
ﬁve genotypes were then combined into a sum score.
The overall nonresponse rate was 23.4% for the UC
cases. OR of nonresponse dependent on the sum score
of the ﬁve selected genotypes is shown in Figure 3.
Patients who were carriers of all ﬁve genotypes had an
OR of 25 (95% CI: 1.93–323.55) for nonresponse (Fig-
ure 3). Positive and negative predictive values for the
sum scores are shown in Table 5. No variations or com-
bination of variations could produce negative predictive
values above 0.5 (ranging from 0.0 to 0.5). The positive
Table 2 | (Continued)
Disease References
# SNPs
assigned
# sign
SNPs
Gene (rs-number)
Signiﬁcant SNPs Nonsigniﬁcant SNPs
UC Bank et al.25 36 11 TLR2 (rs3804099)
TLR2 (rs11938228)
TLR2 (rs4696480)
TLR4 (rs5030728)
LY96 (rs11465996)
CD14 (rs2569190)
TNFAIP3 (rs6927172)
IL1B (rs4848306)
IL1RN (rs4251961)
IL6 (rs10499563)
IL17A (rs2275913)
TLR2 (rs1816702), TLR4(rs1554973, rs12377632),
TLR5 (rs5744168), TLR9 (rs187084, rs352139),
MAP3K14 (rs7222094), SUMO4 (rs237025),
NFKBIA (rs696), NFKB1 (rs28362491),
TNF (rs1800629, rs361525),
TNFRSF1A (rs4149570), IL1B (rs1143623,
rs1143627), IL4R (rs1805010), IL6R
(rs4537545), IL10 (rs1800872, rs3024505),
IL23R (rs11209026), IFNG (rs2430561), TGFB1
(rs1800469), PTPN22 (rs2476601), PPARG
(rs1801282), NLRP3 (rs4612666)
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Table 3 | Odds ratio (OR) and 95% conﬁdence interval (95% CI) for the association between anti-TNF treatment
clinical response and polymorphisms for polymorphisms investigated in more than one individual cohort using clinical
response criteria
Disease Gene rs number OR (95% CI) MAF Model Criteria*
Response
groups Reference
Pathogen recognition
CD TLR2 rs3804099 2.02 (1.17–3.49) C TC or CC vs. TT SCTSS R vs. N and P Bank et al.25
UC 2.47 (0.98–6.23) C CC vs. TC or TT SCTSS R vs. N Bank et al.25
UC TLR2 rs11938228 0.49 (0.26–0.90) A CA or AA vs. CC SCTSS R vs. N Bank et al.25
CD 0.74 (0.43–1.28) A CA or AA vs. CC SCTSS R vs. N Bank et al.25
CD TLR2 rs1816702 2.02 (1.04–3.95) T CT or TT vs. CC SCTSS R vs. N and P Bank et al.25
UC 1.16 (0.48–2.82) T CT or TT vs. CC SCTSS R vs. N and P Bank et al.25
UC TLR2 rs4696480 0.29 (0.12–0.70) T TT vs. AA or AT SCTSS R vs. N and P Bank et al.25
CD 1.31 (0.67–2.56) T TT vs. AA or AT SCTSS R vs. N and P Bank et al.25
CD TLR4 rs5030728 3.34 (1.32–8.47) A GA vs. GG SCTSS R vs. N Bank et al.25
UC 2.89 (1.17–7.12) A AA vs. GG SCTSS R vs. N and P Bank et al.25
CD LY96 rs11465996 1.73 (1.01–2.90) G CG or GG vs. CC SCTSS R vs. N Bank et al.25
UC 0.32 (0.14–0.75) G CG or GG vs. CC SCTSS R vs. N and P Bank et al.25
CD TLR9 rs352139 0.38 (0.16–0.94) A AA vs. GA or GG SCTSS R vs. N Bank et al.25
UC 0.55 (0.16–1.84) A AA vs. GA or GG SCTSS R vs. N Bank et al.25
CD NOD2 rs2066844 1.77 (0.71–4.99)† T TT or CT vs. CC CDAI R and P vs. N Vermeire et al.38
CD 0.84 (0.48–1.48)† T TT or CT vs. CC CDAI R vs. N Mascheretti et al.26
CD no.a. T TT or CT vs. CC IBDQ R vs. N Koder et al.37
CD NOD2 rs2066845 0.55 (0.19–1.69)† C CC or CG vs. GG CDAI R and P vs. N Vermeire et al.38
CD 1.19 (0.56–2.61)† C CC or CG vs. GG CDAI R vs. N Mascheretti et al.26
CD no.a. C CC or CG vs. GG IBDQ R vs. N Koder et al.37
CD NOD2 rs41450053 0.57 (0.19–1.65)† C CC or CG vs. GG CDAI R and P vs. N Vermeire et al.38
CD 1.10 (0.53–1,92)† C CC or CG vs. GG CDAI R vs. N Mascheretti et al.26
CD no.a. C CC or CG vs. GG IBDQ R vs. N Koder et al.37
UC CD14 rs2569190 0.54 (0.30–0.98) A GA or AA vs. GG SCTSS R vs. N and P Bank et al.25
CD 0.95 (0.60–1.52) A GA or AA vs. GG SCTSS R vs. N and P. Bank et al.25
Cytokines
UC TNF rs1800629 1.17 (0.46–2.97) A GA or AA vs. GG SCTSS R vs. N and P Bank et al.25
CD 1.15 (0.66–2.01) A GA or AA vs. GG SCTSS R vs. N and P Bank et al.25
CD 0.60 (0.30–1.22)† A GA or AA vs. GG CDAI R vs. N Louis et al.28
CD no.a. A GA or AA vs. GG CDAI R and P vs. N Mascheretti et al.27
CD TNFRSF1A rs4149570 2.39 (1.03–5.57) T TT vs. GG SCTSS R vs. N and P Bank et al.25
UC 1.56 (0.41–5.88) T TT vs. GG SCTSS R vs. N and P Bank et al.25
CD TNFRSF1B rs1061622 0.88 (0.57–1.37)† G TG or GG vs. TT CDAI R and P vs. N Mascheretti et al.27
CD 1.52 (0.79–3.04)1 G TG or GG vs. TT HBI R vs. N Medrano et al.36
UC TNFAIP3 rs6927172 0.34 (0.13–0.88) G CG or GG vs. CC SCTSS R vs. N and P Bank et al.25
CD 1.06 (0.51–2.21) G CG or GG vs. CC SCTSS R vs. N and P Bank et al.25
CD IFNG rs2430561 1.97 (1.13–3.42) A TA or AA vs. TT SCTSS R vs. N and P Bank et al.25
UC 1.21 (0.52–2.85) A TA or AA vs. TT SCTSS R vs. N and P Bank et al.25
UC IL1B rs4848306 2.69 (1.04–6.94) A GA or AA vs. GG SCTSS R vs. N Bank et al.25
CD 1.55 (0.73–3.29) A GA or AA vs. GG SCTSS R vs. N Bank et al.25
UC IL1RN rs4251961 0.42 (0.18–0.98) C TC or CC vs. TT SCTSS R vs. N and P Bank et al.25
CD 0.88 (0.52–1.50) C TC or CC vs. TT SCTSS R vs. N and P Bank et al.25
UC IL6 rs10499563 3.60 (1.39–9.29) C TC or CC vs. TT SCTSS R vs. N and P Bank et al.25
CD 1.09 (0.64–1.84) C TC or CC vs. TT SCTSS R vs. N and P Bank et al.25
UC IL10 rs3024505 1.41 (0.61–3.26) A GA or AA vs. GG SCTSS R vs. N and P Bank et al.25
CD 1.41 (0.61–1.79) A GA or AA vs. GG SCTSS R vs. N and P Bank et al.25
CD no.a. A A vs. G IBDQ R vs. N Koder et al.37
UC IL17A rs2275913 0.42 (0.18–1.00) A GA or AA vs. GG SCTSS R vs. N and P Bank et al.25
CD 1.42 (0.85–2.37) A GA or AA vs. GG SCTSS R vs. N and P Bank et al.25
Antibody-dependent immune responses
CD FCGR3A rs396991 no.a T TT vs. TG or GG CDAI R and P vs. N Louis et al.29
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predictive values, however, were very high for some
genetic proﬁles. In particular, the group of 26 patients
(corresponding to 11% of the UC patients) without any
of the ﬁve low-response associated genotypes had a posi-
tive predictive value of 0.96.
DISCUSSION
In this review, we wanted to identify genetic polymor-
phisms associated with treatment outcome from anti-
TNF treatment in IBD patients in order to suggest
potential biomarker candidates for further evaluation of
predictive potential. Replication of genetic associations
that are not genome-wide signiﬁcant (combined
P < 5 9 108) in the initial screening, is of major
importance to provide robust statistical evidence.
Accordingly we included all polymorphisms, which were
studied in at least two studies and where data on geno-
type and treatment response could be retrieved, in meta-
analyses. Our meta-analysis which included both CD
and UC and which was based on clinical response crite-
ria showed that polymorphisms in TLR2, TLR4, TLR9,
TNFRSF1A, IFNG, IL6 and IL1B were associated with
treatment response.
Additionally, using biological response criteria, we
found a polymorphism in FCGR3A, which was
associated with anti-TNF treatment response in CD
patients, and for which a functional effect was indi-
cated.35
Furthermore, to explore the potential use of genetic
markers for predicting treatment response, we calculated
predictive values in UC using the dataset from one of
the included studies.25 We calculated positive and
Table 3 | (Continued)
Disease Gene rs number OR (95% CI) MAF Model Criteria*
Response
groups Reference
CD no.a T TT vs. TG or GG CDAI R vs. N Louis et al.34
CD no.a T TT vs. TG or GG CDAI R vs. N Moroi et al.35
CD >1 T TT or TG vs. GG IBDQ R vs. N Koder et al.37
Apoptosis
CD FAS rs1800682 0.69 (0.34–1.42)† T CC or CT vs. TT CDAI R vs. N Hlavaty et al.
CD >1 T TT vs. CC or CT IBDQ R vs. N Koder et al.37
CD >1 T T vs. C DIBDQ R vs. N Koder et al.37
CD CASP9 rs4645983 1.50 (1.34–1.68)† T TT vs. CC or CT CDAI R vs. N Hlavaty et al.39
CD >1 T CT or TT vs. CC IBDQ R vs. N Koder et al.37
CD >1 T CT or TT vs. CC DCRP R vs. N Koder et al.37
CD >1 T T vs. C IBDQ R vs. N Koder et al.37
no.a., No association; R, Responder; N, nonresponder; P, partial responder; IBDQ, IBD questionnaire; SCTSS, Simple Clinical Three
Step Scale; HBI, Harvey–Bradshaw index; CDAI, Crohn’s disease activity index; CRP, C-reactive protein; MAF, minimal allele
frequency.
* For response criteria please refer to Table 1.
† OR and CI calculated from the data obtained from the article.
Table 4 | Odds ratio (OR) and 95% conﬁdence interval (95% CI) for the association between anti-TNF treatment
biological response and polymorphisms for polymorphisms investigated in more than one individual cohort using
biological response criteria
Disease Gene rs number OR (95% CI) MAF Model Criteria* Response groups Reference
Antibody-dependent immune responses
CD FCGR3A rs396991 1.43 (1.27–1.61)* T TT vs. TG or GG DCRP R and P vs. N Louis et al.29
CD >1 T TT vs. TG or GG DCRP R vs. N Louis et al.34
CD >1 T TT vs. TG or GG DCRP R vs. N Moroi et al.35
no.a., No association; R, Responder; N, nonresponder; P, partial responder; IBDQ, IBD questionaire; CRP, C-reactive protein; MAF,
minimal allele frequency.
* For response criteria please refer to Table 1.
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negative prediction values for sum scores of ﬁve selected
genotypes in IL12B, IL6 and TLR2. High positive predic-
tive values could be achieved for some patient groups,
including a positive predictive value of 0.96 for UC
patients without any of the ﬁve selected genotypes.
Although these exploratory results give hope for the
potential of genetics for treatment selection, they need
validation and conﬁrmation in larger cohorts before
taken into clinical practice.
An explorative approach was used when identifying
potential candidate biomarkers in order not to overlook
potential candidates. Response criteria varied between
the reviewed studies and more than one criterion were
often used in the individual studies. For example,
FCGR3A was identiﬁed as a potential biomarker using
CRP levels (deﬁned as biological response), whereas the
same studies found no signiﬁcant associations using clin-
ical response criteria.29, 34, 35 IBD comprises a
Study
ID
Odds
ratio (95% CI)
%
Weight n
Favours non-
response
Favours beneficial
response
TLR2_rs3804099
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
2.02 (1.18, 3.45)
2.47 (1.00, 6.12)
2.17 (1.35, 3.47)
TLR4_rs5030728
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
TNFRSF1A_rs4149570
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
IFNG_rs2430561
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
IL1B_rs4848306
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
IL6_rs10499563
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
TLR2_rs11938228
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
TLR9_rs352139
Bank et al., 2014 CD
Bank et al., 2014 UC
Result
3.34 (1.34, 8.31)
2.89 (1.19, 6.99)
3.18 (1.63, 6.21)
2.39 (1.04, 5.48)
1.56 (0.43, 5.73)
2.06 (1.02, 4.17)
1.97 (1.15, 3.38)
1.21 (0.52, 2.80)
1.66 (1.05, 2.63)
2.69 (1.06, 6.81)
1.55 (0.74, 3.24)
1.88 (1.05, 3.35)
3.60 (1.42, 9.12)
1.09 (0.65, 1.82)
1.65 (1.04, 2.63)
0.49 (0.27, 0.89)
0.74 (0.43, 1.27)
0.64 (0.43, 0.96)
0.38 (0.16, 0.92)
0.55 (0.17, 1.80)
0.43 (0.21, 0.88)
65.31
34.69
100.00
65.31
34.69
100.00
65.31
34.69
100.00
65.31
34.69
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65.31
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34.69
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Figure 2 | Forest plot of signiﬁcant associations between polymorphisms and treatment response including
polymorphisms with available data. Data from Bank et al.25
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heterogeneous group of subtypes with different molecu-
lar characteristic41 and characterised by variable disease
activity and this may challenge the identiﬁcation of
biomarkers. Therefore, using clearly deﬁned biological
response criteria such as e.g. CRP or, maybe even better,
f-calprotectin, in a subgroup of patients may thus be a
successful strategy to identify candidate biomarkers.
Clinical response rate has been found to be higher in
patients with elevated CRP levels than those with normal
CRP values.29
Generally, interpretation of genetic information in a
meaningful way may be difﬁcult. The use of functional
polymorphisms, i.e. polymorphisms that cause, or are
linked to polymorphisms that change enzyme activity of
the encoded protein, is a means to help understanding
the underlying biological mechanisms. FCGR3A encodes
a receptor for immunoglobulin G (IgG), FccRIIIa. Moroi
et al.35 suggested that the high response rate observed
among the TT genotype carriers was caused by high
binding of inﬂiximab to FccRIIIa on the NK cells leading
to high antibody-dependent cell-mediated cytotoxicity.
The results from this review therefore suggest that
FCGR3A, which is involved in the antibody-dependent
immune response, is important for anti-TNF treatment
response in IBD. In contrast, a meta-analysis found no
associations between the FCGR3A rs396991 polymor-
phism and the anti-TNF response among patients with
rheumatoid arthritis,42 indicating discrepancies in the
potential of this polymorphism to predict the response
to anti-TNF treatment in patients with chronic inﬂam-
matory diseases. Potentially, the FCGR3A rs396991 poly-
morphism may deﬁne a subset of patients with chronic
inﬂammatory diseases who may beneﬁt from anti-TNF
treatment.
Our meta-analyses included all polymorphisms that
were investigated in more than one cohort. However, all
included polymorphisms derived from only one study25
that studied the same polymorphisms in both CD and
UC. Therefore, the generality of the meta-analyses can
be questioned. The results suggest that genes involved in
the innate immune response such as recognition of bac-
terial components (TLR2, TLR4, TLR9) and cytokine
pathways (TNFRSF1A, IFNG, IL6 and IL1B) are impor-
tant for anti-TNF treatment response. These factors are
of most importance for keeping the balance between
intestinal homeostasis and inﬂammation.4 Thus, this
meta-analysis suggests that host–microbial interaction
play a role in IBD treatment response. In line with this
notion, the dysbiosis in the gut microbiota in patients
with rheumatoid arthritis patients was found to partly
resolve after medical treatment.43
Current knowledge on the mechanisms involved in
anti-TNF treatment of IBD was recently reviewed.9 Iden-
tiﬁcation of genetic variants that are associated with a
biological process is a method for identiﬁcation of the
involved genes.19, 20, 44, 45 Here, we propose a method to
evaluate the involvement of supposed underlying biologi-
cal mechanisms. Thereby, important mechanisms
involved in treatment outcome in IBD patients in clinical
practice may be identiﬁed. Furthermore, negative ﬁnd-
ings may suggest that the studied genes are not of major
importance in treatment response provided that the
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Figure 3 | OR for the presence of one or more of ﬁve
selected genotypes for predicting anti-TNF
nonresponse. Data from Bank et al.25 Genotypes: TLR2
rs4696480TT, TLR2 rs11938228AC, IL6 rs10499563TT,
IL12B rs3212227AC and IL12B rs3212217CG. Present = 1,
absent = 0. Sum score is shown. CIs are omitted due
to frequent extreme ranges. *P < 0.05, **P < 0.01.
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studied polymorphisms are functional in the
target tissues and that studies had sufﬁcient statistical
power.
However, environmental factors such as nutrition, life
style, and other medication may impact intestinal
immunity and may also interact with genetic susceptibil-
ity. These factors may not have been captured in the
included studies. Thus, potential predictive biomarkers
may not have been identiﬁed in the present review due
to e.g. interactions with environmental factors, which
differ between populations, as well as genetic hetero-
geneity. Likewise, potential statistical errors in the anal-
ysed studies may affect the results of this review. This
review did not have power to perform separate analyses
for various anti-TNF drugs, such as Inﬂiximab and
Adalimumab. Candidate gene studies are based on bio-
logical hypotheses as they rely on the evaluation of poly-
morphisms selected in pathways thought to be involved
in treatment response. Therefore, we did not correct for
multiple comparisons. Instead, in genetic studies, repli-
cation of ﬁndings in other cohorts is considered as a
critical criterion. We found 18 genes that were investi-
gated in more than one cohort whereof 11 genes were
only investigated in Danish IBD patients. Remarkable,
all the identiﬁed candidates in the meta-analyses were
from the Danish study. This group of patients may have
been genetic homogeneous and characterised by similar
lifestyle factors which may have contributed to the
results.
Another important issue is the analysis of the com-
bined effects of various networks, including gene-gene
interactions. In addition, new biologics directed against
inﬂammatory pathways involved in IBD4 such as inter-
leukin (IL)-6, IL-12/23, a4-integrins, IL-17, interferon-c
are currently under implementation or development.
There is some support of the notion that inﬂammation
may be driven by genetically high activity of IL-1b,
interferon-c and/or IL-6 in anti-TNF nonresponders.25
The new biologics may therefore potentially be effective
in subgroups of patients with certain genetic constitu-
tions, for example, biologics directed against IL-17 or
interferon-c may be more effective in patients with an
immune response mediated by genetically determined
high IL-17 or interferon-c immune responses. The evalu-
ation of these questions requires testing a large number
of polymorphisms in large cohorts of well-characterised
patients and may be performed by large international
working groups such as the International IBD Genetics
Consortium.41, 46, 47 Future strategies may combine
genetic markers indicating which pathways and cytoki-
nes are deregulated and potentially affected drug degra-
dation pathways together with information on e.g.
clinical, serological, and microbial proﬁles in each case
for the selection of the best treatment for each patient.
New ways of analysing the large amount of genetic data,
integrating these with other information and moreover,
translating the results into clinical practice will be neces-
sary for achieving these goals.
In conclusion, only few and weak biomarker candi-
dates were identiﬁed for further evaluation of their
treatment prediction potential. Thus, the basis for per-
sonalised medicine, i.e. the ability to stratify the
patients according to the expected response to anti-
TNF treatment, is not yet available. Genetic biomarkers
have the advantage that they do not change over time.
Therefore, hypothesises-free approaches testing a large
number of polymorphisms in large well-characterised
cohorts are warranted in order to identify biomarkers
which can be used for treatment selection in the clini-
cal setting.
Table 5 | Odds ratios (OR), 95% conﬁdence intervals (95% CI), positive (PPV) and negative predictive values (NPV)
for sum scores of 5 selected genotypes
Full or partial response (N = 179) Nonresponse (N = 60) OR 95% CI PPV NPV
Number of variants
None (N = 26) 25 1 1 (ref) 0.96 0.04
1 (N = 82) 58 17 7.33 0.92–58.10 0.77 0.23
2 (N = 68) 45 21 11.67* 1.48–91.98 0.68 0.32
3 (N = 45) 33 10 7.58 0.91–63.13 0.77 0.23
4 (N = 23) 15 8 13.33* 1.51–117.38 0.65 0.35
5 (N = 6) 3 3 25.00* 1.93–323.55 0.50 0.50
Data from Bank et al.25
Genotypes: TLR2 rs4696480TT, TLR2 rs11938228AC, IL6 rs10499563TT, IL12B rs3212227AC, and IL12B rs3212217CG.
* P < 0.05.
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